TGA Adds New Classification Rule in September 2026: Non-Invasive Saline-Only Devices Such as Pre-Filled Saline Flush Syringes Classified as Class IIa

TGA Adds New Classification Rule in September 2026: Non-Invasive Saline-Only Devices Such as Pre-Filled Saline Flush Syringes Classified as Class IIa

Published: 2 October 2026, 19:32 | Category: Classification and Technical Guidance

What Has Changed

On 8 September 2026, the Australian Therapeutic Goods Administration (TGA) announced on its website that Part 2 of Schedule 2 to the Therapeutic Goods (Medical Devices) Regulations 2002 has been amended to introduce a new classification rule for a specific group of non-invasive medical devices. The amendment is set out in the Therapeutic Goods Legislation Amendment (2026 Measures No. 1) Regulations 2026, Federal Register of Legislation ID F2026L01167. The instrument is recorded on the Federal Register of Legislation as having commenced, is administered by the Department of Health, Disability and Ageing, and is made under the Therapeutic Goods Act 1989.

Scope of the New Rule

Under the newly inserted clause 2.2, a device is classified as Class IIa where it meets all of the following conditions:

• It is a non-invasive device;
• It contains only saline (normal saline); and
• Its intended purpose is to maintain the patency of, or to flush, the lumen of another medical device.

The examples cited by the TGA are pre-filled saline flush syringes and locking solutions for vascular access devices. Such products are used in large volumes in ward nursing, catheter maintenance and interventional procedures, and constitute routine hospital consumables.

Difference from the Previous Approach

Previously, there was ambiguity in how these saline-only products were classified. The TGA has confirmed that this amendment also clarifies the boundary of clause 5.1: clause 5.1 continues to apply to medical devices that contain a medicine, while products containing only saline are handled under the new clause 2.2 and classified as Class IIa. In other words, whether or not a medicine is present is the dividing line between the two rules, rather than simply whether the product is used for flushing. This distinction is particularly important for companies with broad product portfolios, as the same manufacturer frequently produces both medicine-containing and saline-only products.

Effective Dates and Transitional Arrangements

The new classification rule applies from 7 September 2026 to inclusion applications submitted to the Australian Register of Therapeutic Goods (ARTG). Devices that had already obtained ARTG registration before that date, and applications already lodged before that date, benefit from a five-year transition period from that date in which to meet the new requirements. For company planning purposes, this means that existing products do not cease to be valid immediately, but five years is not indefinite, and the earlier a portfolio is reviewed, the more options remain available.

Who Needs to Pay Attention

Directly affected are manufacturers of pre-filled saline flush syringes, locking solutions and various catheter flush accessories, as well as the Australian sponsors who handle ARTG inclusion on their behalf. Indirectly affected are the regulatory compliance teams preparing technical documentation and evidence of conformity for these products. A higher classification typically means that the conformity assessment route, the depth of technical documentation and the requirements for quality system evidence will change accordingly, rather than merely altering a registration attribute.

What the Announcement Does Not Clarify

The TGA announcement addresses the classification rule itself only. It does not elaborate on the specific conformity assessment procedures applicable to the various product types under Class IIa, nor does it provide operational guidance on how existing certificates should be transitioned during the transition period. Companies already holding relevant ARTG registrations should determine, product by product, whether their products contain a medicine and whether they are strictly limited to normal saline, and confirm which rule applies, rather than defaulting to the previous classification position.

AIMEILI Regulatory Interpretation

The amendment resolves a long-standing classification grey zone for saline-only flush and lock products, but it does so by raising the classification outcome rather than by lowering the evidence burden. Clause 2.2 is deliberately narrow: it is triggered only where all three conditions — non-invasive status, saline-only composition, and an intended purpose of maintaining patency or flushing the lumen of another medical device — are satisfied concurrently. Where a product contains any active substance, including heparin, citrate, an antimicrobial agent or any other medicine, clause 5.1 continues to apply and the product remains on the combination product pathway. Conversely, where a saline product is intended for a different purpose, such as wound irrigation, reconstitution or general fluid delivery, clause 2.2 should not be assumed to apply and the classification should be justified against the remaining provisions of Schedule 2.

A second interpretive point concerns the practical meaning of the five-year transition. The transition preserves the validity of existing ARTG registrations and of applications already lodged, but it does not suspend the sponsor's ongoing obligations, nor does it automatically extend to variations, new presentations, new manufacturing sites or new intended purposes added after 7 September 2026. In practice, the transition should be treated as a planning horizon for re-documentation and re-assessment, not as a freeze on regulatory change. Companies should also note that the TGA does not, in this announcement, specify the conformity assessment procedure to be applied, and the applicable route should be confirmed against the current regulatory framework and any subsequent TGA guidance.

Business Impact

• Reclassification of existing portfolios: Saline-only flush syringes and vascular access locking solutions that were previously registered at a lower classification will, on transition, need evidence commensurate with Class IIa. Manufacturers should map every SKU against the three clause 2.2 conditions now, because portfolio lines frequently share branding and packaging while differing in composition.
• Conformity assessment and technical documentation: Class IIa generally requires conformity assessment procedures involving assessment of the manufacturer's quality system and assessment of the technical documentation. Budgets, timelines and notified body or TGA assessment capacity should be planned well ahead of the transition deadline.
• Sponsor and supply continuity: Australian sponsors should confirm with their overseas manufacturers which products fall under clause 2.2, and agree on responsibilities for updated technical files, labelling and instructions for use, so that supply to hospitals and catheter care settings is not interrupted.
• Portfolio segmentation by medicine content: Companies producing both medicine-containing and saline-only products should now maintain a clear internal split in regulatory strategy documentation, since the two product families will follow different rules under clause 5.1 and clause 2.2 respectively.
• Documentation of intended purpose: Because the rule turns on intended purpose, claims in labelling, instructions for use, promotional material and tender documentation should be aligned with the classification position adopted, to avoid inconsistency between the registered intended purpose and commercial messaging.
• Planning horizon: Existing registrations remain valid during the transition, but the five-year window is finite. Early gap analysis, particularly for large consumable ranges and for products supplied under hospital tenders, will reduce the risk of last-minute assessment bottlenecks.

Sources and Verification

• Therapeutic Goods Administration (TGA), news article "Updated classification rules for certain combination products", 8 September 2026: https://www.tga.gov.au/news/news-articles/updated-classification-rules-certain-combination-products
• Therapeutic Goods Legislation Amendment (2026 Measures No. 1) Regulations 2026, Federal Register of Legislation (Australia) ID F2026L01167: https://www.legislation.gov.au/F2026L01167/latest/text
• Therapeutic Goods Administration (TGA), "Boundary and combination products" topic page: https://www.tga.gov.au/products/boundary-combination

Scope of verification and access date: Verification was performed on 2 October 2026, with visits to the TGA news article page, the legislative text page on the Federal Register of Legislation, and the TGA "Boundary and combination products" topic page, confirming the announcement date, clause numbering, application date and the five-year transition period as stated.

Applicability note: This article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment in respect of any specific product, company or registration application. Classification determinations are governed by the official legal text and the specific attributes of the product, and the information may change with subsequent official updates.